The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes the use of miniature lungs and colons to help test Covid-19 treatments.
British scientists analyzing data from a widely used Covid-19 symptom-tracking app have found there are six distinct types of the disease, each distinguished by a cluster of symptoms.
Some 170 people who spent time in Yosemite National Park in recent weeks have suffered from a gastrointestinal ailment “consistent with norovirus” and two have been diagnosed with the illness, park officials said.
The old adage that drinking beer before wine prevents hangovers turns out to be a myth, German researchers say.
U.S. health regulators approved Amicus Therapeutics’ Galafold as the first oral therapy to treat Fabry disease, a rare and sometimes fatal condition.
According to Reuters UK, Japan’s Takeda Pharmaceutical made an official bid to acquire London’s Shire for about $60 billion, which was rejected.
The U.S. Food and Drug Administration approved French drugmaker Advanced Accelerator Application SA’s drug to treat patients with a type of digestive tract cancer.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business
Ionis Pharmaceuticals and Janssen strengthened their alliance with a second deal for gastrointestinal drugs. Janssen put up $5 million to secure the licensing of Ionis’ antisense drug, IONIS-JBI2-2.5RX.